more

Amedisys (AMED)

(Real Time Quote from BATS)

$96.87 USD

+0.07 (0.07%)

Updated Nov 8, 2024 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

Top 20% (51 out of 251)

Industry: Medical - Outpatient and Home Healthcare

View All Zacks #1 Ranked Stocks

Zacks News

Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline

by Zacks Equity Research Published on April 29,2020

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AMEDPositive Net Change

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

by Zacks Equity Research Published on April 23,2020

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AMEDPositive Net Change

Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher

by Zacks Equity Research Published on April 23,2020

Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

medical

Add These 4 Stocks With Remarkable Interest Coverage Ratio

by Sumit Singh Published on April 22,2020

Debt, which is crucial for most of the companies to finance operations, comes at a cost called interest. Interest expense has a direct bearing on the profits of a company.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on April 16,2020

Is (AMED) Outperforming Other Medical Stocks This Year?

AMEDPositive Net Change

Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts

by Zacks Equity Research Published on April 16,2020

To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.

Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know

by Zacks Equity Research Published on April 15,2020

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

AMEDPositive Net Change

Amedisys (AMED) Upgraded to Buy: Here's Why

by Zacks Equity Research Published on April 15,2020

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMEDPositive Net Change

Amedisys (AMED) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on April 15,2020

Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AMEDPositive Net Change

Amedisys Gains on Expanding Hospice Arm, Favorable Demography

by Zacks Equity Research Published on April 15,2020

Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.

medical

Amedisys (AMED) Stock Moves -0.87%: What You Should Know

by Zacks Equity Research Published on March 23,2020

In the latest trading session, Amedisys (AMED) closed at $168.20, marking a -0.87% move from the previous day.

AMEDPositive Net Change

Here's Why You Should Retain Amedisys (AMED) Stock for Now

by Zacks Equity Research Published on March 23,2020

Investor confidence is high in Amedisys (AMED) stock, thanks to solid prospects.

medical

Why Is Amedisys (AMED) Down 16.2% Since Last Earnings Report?

by Zacks Equity Research Published on March 19,2020

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMEDPositive Net Change

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research Published on March 12,2020

LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.

medical

Scoop Up These 5 Promising Interest Coverage Ratio Stocks

by Sumit Singh Published on March 04,2020

Interest expense has a direct bearing on the profits of a company and the company's creditworthiness depends on how effectively it meets its interest obligations.